Protara Therapeutics stock tumbles after $75M public offering By Investing.com
Protara Therapeutics stock tumbles after $75M public offering…
5,896$
2,72%
Echtzeit-Aktienkurs Protara Therapeutics Inc.
Bid:
Ask:
Nachrichten zur Protara Therapeutics Inc. Aktie
Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies…
Protara Therapeutics stock drops following interim trial results By Investing.com
Protara Therapeutics stock drops following interim trial results…
Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC
NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies…
Protara Therapeutics (TARA) Moves to Buy: Rationale Behind the Upgrade
Protara Therapeutics (TARA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the companys earnings prospects.…
Protara Therapeutics: Speculative Buy On Promising TARA-002 Trial Results
…
Protara Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies…
Protara Announces Closing of $100 Million Public Offering
NEW YORK, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative…
Protara Announces Proposed Public Offering
NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing…
Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC
NEW YORK, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative…
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Thursday, December 5, 2024
NEW YORK, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies…
Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology
NEW YORK, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies…
Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update
NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies…
Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference
NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies…
Protara Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update
NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies…
Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing…
Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update
NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies…
Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies…